DeciBio
Mané Mikayelyan is a Project Leader at DeciBio since September 2019. With experience as a Senior Associate, Associate, Senior Analyst, and Analyst, Mané contributes to providing strategic insights and market intelligence for precision medicine and life sciences at DeciBio. Previously, Mané worked as a Research Assistant at the University of California, San Francisco, exploring translational genomics research related to prostate cancer. During a brief externship at Mirvie, a biotech company, Mané gained experience in product development strategy. Mané graduated from the University of California, Berkeley with a degree in Integrative Biology, Human Biology and Health Sciences, and Biology.
DeciBio
1 followers
DeciBio Consulting is a boutique strategy consulting firm focusing on the life science industry. DeciBio's mission is to provide the strategic insights that accelerate the development, adoption, and accessibility of personalized medicine. Headquartered in Los Angeles, CA, DeciBio serves clients and customers across the globe, ranging from incubator-stage startups to Fortune 500 life science corporations. DeciBio addresses business solutions that range from market landscape analyses to full commercial strategies, including organic and inorganic growth opportunities (commercial due diligences). DeciBio’s work is typically supported by a mix of primary and secondary research leveraging Dexter, its in-house expert network, and DeciBio Analytics’ proprietary data intelligence products. DeciBio’s Analytics division offers numerous data products to support strategic insights, including in clinical diagnostics (the DxBooks), immuno-oncology (the I/O BioMAP), omics market segmentation (the MarketBooks), and the entire life sciences industry (BioTrack). Internal teams such as the Culture Committee, Women* in Consulting, and Gays in Consulting enrich the employee experience. DeciBio’s Social Impact board and the DeciBio Impact Lab work collaboratively across divisions and externally to uproot discrimination and increase access to precision medicine.